Boston Scientific Sees Unusually Large Options Volume (NYSE:BSX)

Boston Scientific Corporation (NYSE:BSX) was the target of unusually large options trading activity on Tuesday. Traders acquired 113,986 call options on the company. This is an increase of 205% compared to the typical daily volume of 37,315 call options.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Jefferies Financial Group cut their price target on Boston Scientific from $100.00 to $67.00 and set a “buy” rating for the company in a research note on Wednesday, June 24th. Royal Bank Of Canada cut their target price on Boston Scientific from $85.00 to $70.00 and set an “outperform” rating on the stock in a report on Thursday, July 30th. Leerink Partners set a $60.00 price objective on shares of Boston Scientific in a report on Thursday, July 30th. Oppenheimer decreased their price target on Boston Scientific from $90.00 to $85.00 and set an “outperform” rating for the company in a research report on Monday, July 27th. Finally, Bank of America cut their price objective on Boston Scientific from $105.00 to $68.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. Twenty-four investment analysts have rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $71.62.

Insider Activity

In related news, Director Edward J. Ludwig bought 5,000 shares of Boston Scientific stock in a transaction that occurred on Friday, July 31st. The stock was purchased at an average cost of $45.48 per share, with a total value of $227,400.00. Following the purchase, the director owned 30,359 shares in the company, valued at approximately $1,380,727.32. This trade represents a 19.72% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David C. Habiger purchased 2,100 shares of Boston Scientific stock in a transaction that occurred on Wednesday, August 5th. The shares were bought at an average cost of $47.59 per share, with a total value of $99,939.00. Following the completion of the transaction, the director directly owned 17,160 shares of the company’s stock, valued at approximately $816,644.40. The trade was a 13.94% increase in their position. The SEC filing for this purchase provides additional information. In the last 90 days, insiders have acquired 194,522 shares of company stock worth $9,385,210. 0.34% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in BSX. Corient Private Wealth LP boosted its position in Boston Scientific by 25.3% during the second quarter. Corient Private Wealth LP now owns 233,728 shares of the medical equipment provider’s stock worth $9,976,000 after purchasing an additional 47,125 shares during the period. Amundi raised its position in shares of Boston Scientific by 1.2% in the second quarter. Amundi now owns 14,296,121 shares of the medical equipment provider’s stock valued at $610,158,000 after purchasing an additional 173,208 shares during the period. Affinity Wealth LLC purchased a new stake in shares of Boston Scientific during the 2nd quarter valued at approximately $76,000. Brown Financial Advisors lifted its stake in shares of Boston Scientific by 59.0% during the 2nd quarter. Brown Financial Advisors now owns 20,881 shares of the medical equipment provider’s stock valued at $891,000 after buying an additional 7,749 shares in the last quarter. Finally, California State Teachers Retirement System boosted its holdings in Boston Scientific by 4,113.5% in the 2nd quarter. California State Teachers Retirement System now owns 96,909,037 shares of the medical equipment provider’s stock worth $4,136,078,000 after buying an additional 94,609,083 shares during the period. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Performance

Shares of BSX stock traded down $0.25 during trading hours on Tuesday, hitting $48.05. 12,000,371 shares of the company were exchanged, compared to its average volume of 18,477,602. The firm has a fifty day simple moving average of $46.65 and a 200 day simple moving average of $56.35. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. Boston Scientific has a 52-week low of $42.20 and a 52-week high of $109.50. The stock has a market capitalization of $69.64 billion, a price-to-earnings ratio of 19.45, a P/E/G ratio of 1.02 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating the consensus estimate of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The business had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. During the same quarter in the prior year, the business earned $0.75 earnings per share. Boston Scientific’s revenue for the quarter was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Research analysts predict that Boston Scientific will post 3.3 earnings per share for the current fiscal year.

Boston Scientific announced that its Board of Directors has initiated a stock buyback plan on Monday, May 18th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s board of directors believes its stock is undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.